BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 25838343)

  • 1. Pathogenesis beyond the cancer clone(s) in multiple myeloma.
    Bianchi G; Munshi NC
    Blood; 2015 May; 125(20):3049-58. PubMed ID: 25838343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
    Bianchi G; Anderson KC
    CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.
    Bianchi G; Ghobrial IM
    Curr Cancer Ther Rev; 2014; 10(2):70-79. PubMed ID: 25705146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
    Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
    Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of myeloma.
    Anderson KC; Carrasco RD
    Annu Rev Pathol; 2011; 6():249-74. PubMed ID: 21261519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
    Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
    Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications.
    Salomon-Perzyński A; Jamroziak K; Głodkowska-Mrówka E
    Diagnostics (Basel); 2021 Aug; 11(9):. PubMed ID: 34573876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
    López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
    Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
    Heider M; Nickel K; Högner M; Bassermann F
    Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
    Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
    Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.